Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill for tough blood cancers enters first human tests

NCT ID NCT07619287

Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 15, 2026 · Updated 13 times

Summary

This early-phase trial is testing a new oral drug called BG-75202, alone or with another medicine, in about 118 adults with myeloid blood cancers that have come back or not responded to prior treatment. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BG-75202 (a KAT6A/B inhibitor taken orally, alone or with another drug)
What this could lead to
If it works, this could point toward a new treatment option for certain blood cancers that have not responded to prior therapy.
What could go wrong
This is a very early Phase 1 trial with only 118 participants. The main goal is safety, not proof of effectiveness. Many early-stage drugs fail to show benefit or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 118 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF). * Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories: * Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by patient. * Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Exclusion Criteria: * Prior exposure to KAT6A/B inhibitors/degraders. * A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia. * Known central nervous system involvement by leukemia * Use of antileukemic therapies without sufficient washout period Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myeloid malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloid malignancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    16 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Auckland City Hospital

    RECRUITING

    Auckland, 1023, New Zealand

  • Austin Health

    RECRUITING

    Heidelberg, Victoria, VIC 3084, Australia

  • Concord Repatriation General Hospital

    RECRUITING

    Concord, New South Wales, NSW 2139, Australia

  • Icon Cancer Centre Kurralta Park

    RECRUITING

    Kurralta Park, South Australia, SA 5037, Australia

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch

    RECRUITING

    Tianjin, Tianjin Municipality, 301617, China

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, WA 6009, Australia

  • North Shore Hospital

    RECRUITING

    Auckland, 0622, New Zealand

  • St George Hospital

    RECRUITING

    Kogarah, New South Wales, NSW 2217, Australia

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Nanchang University Branch Xianghu

    RECRUITING

    Nanchang, Jiangxi, 332000, China

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of Zhengzhou Universitysouth Branch

    RECRUITING

    Zhengzhou, Henan, 451161, China

  • The First Hospital of Lanzhou University

    RECRUITING

    Lanzhou, Gansu, 730000, China

  • The Second Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

  • Zhujiang Hospital of Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.